Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Wednesday, 10 May 2017 17:01

Appendix 3B

Wednesday, 10 May 2017 16:56

CLINUVEL Newsletter - May 2017

Tuesday, 02 May 2017 16:54

NICE ENGLAND UPDATE ON SCENESSE®

Melbourne, Australia and Leatherhead, UK, 2 May 2017 CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the Department of Health (DoH) has designated SCENESSE® (afamelanotide 16mg) to be evaluated as a Highly Specialised Technology (HST). The re-classification acknowledges that the National Institute for Health and Care Excellence (NICE) committed an error in its earlier assessment of SCENESSE® as only eligible for review under a Single Technology Appraisal (STA), a mainstream appraisal pathway. The HST referral has been accepted by the UK Secretary of State for Health for the treatment of adult patients with the rare genetic…
Friday, 28 April 2017 17:21

Appendix 4C - Quarterly report

Melbourne, Australia, and Leatherhead, UK, 28 April 2017CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders announced today its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2017.The cash balance as at 31 March 2017 was $18,772,000, a decrease of $788,000 from the end of the previous quarter.Cash receipts for the quarter were $1,597,000 compared to $4,352,000 for the previous quarter. The expected decrease in receipts reflects the seasonal supply cycles of…
Melbourne, Australia, April 12, 2017CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited: Class Number Exercise price CUVAK Conditional Performance Rights subject to various performance milestones, issued various dates under the 2009 and 2014 Plans 25,400 $Nil Consequently, there are now 1,882,260 unlisted conditional performance rights on issue.- End -For more information contact:Darren KeamyCompany SecretaryCLINUVEL PHARMACEUTICALS LIMITEDT: +61 3 9660 4900E: This email address is being protected from spambots. You need JavaScript enabled to view it.-Looking StatementsThis release to the Australian Securities Exchange and to press may contain…
Melbourne, Australia and Leatherhead, UK, US, 12 April 2017 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the treatment of erythropoietic protoporphyria (EPP) patients with CLINUVEL’s drug SCENESSE® (afamelanotide 16mg).CLINUVEL had been in mandatory ‘negotiation’ with GKV-SV since August 2016. Under the German Pharmaceuticals Market Reorganisation Act (AMNOG) a pricing agreement was reached after an Arbitration Board was called. The outcome of the Arbitration Board is legally binding for all state insurers (‘Krankenkassen’) in Germany.aEPP TREATMENT WITH…
Friday, 24 February 2017 19:44

Appendix 4D and Half Year Report

Thursday, 16 February 2017 00:41

CLINUVEL Newsletter - February 2017

Tuesday, 31 January 2017 19:34

Appendix 4C - Quarterly report

Friday, 23 December 2016 20:08

Appendix 3Y

Page 1 of 54

Quick Links